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Abstract Modernmedicine is in the midst of a revolution driven by “big data,” rapidly advancing computing
power, and broader integration of technology into healthcare. Highly detailed and individualized pro-
files of both health and disease states are now possible, including biomarkers, genomic profiles,
cognitive and behavioral phenotypes, high-frequency assessments, and medical imaging. Although
these data are incredibly complex, they can potentially be used to understand multi-determinant
causal relationships, elucidate modifiable factors, and ultimately customize treatments based on in-
dividual parameters. Especially for neurodegenerative diseases, where an effective therapeutic agent
has yet to be discovered, there remains a critical need for an interdisciplinary perspective on data and
information management due to the number of unanswered questions. Biomedical informatics is a
multidisciplinary field that falls at the intersection of information technology, computer and data sci-
ence, engineering, and healthcare that will be instrumental for uncovering novel insights into neuro-
degenerative disease research, including both causal relationships and therapeutic targets and
maximizing the utility of both clinical and research data. The present study aims to provide a brief
overview of biomedical informatics and how clinical data applications such as clinical decision sup-
port tools can be developed to derive new knowledge from the wealth of available data to advance
clinical care and scientific research of neurodegenerative diseases in the era of precision medicine.
 2018 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
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1. Biomedical informatics applications for precision
management of neurodegenerative disease
The practice of medicine is in the midst of a modern-day
revolution, driven by “big data,” rapidly advancing computing
power, and broader integration of technology into health-care
service provision. It is anticipated that from 2014 to 2024,
health-care information technology job growth is expected
to substantially outpace job growth among other industries
[1], due in part to the deluge of health data generated by
new technologies. These data can create highly detailed and
individualized profiles of both health and disease states,
which can potentially be used to understand multi-
determinant causal relationships, elucidate modifiable fac-
tors, and ultimately customize treatments based on individual
parameters. In the case of neurodegenerative diseases
(NDDs), where many questions are still unanswered and
effective therapies have remained elusive, there is a critical
need for an interdisciplinary perspective on data and informa-
tion management to derive novel insights, generate new
knowledge, improve care, and facilitate treatment discovery.
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Biomedical informatics (BMIs) is a multidisciplinary field
that falls at the intersection of information technology, com-
puter and data science, engineering, and healthcare; this inter-
disciplinary intersection will play an integral role in the future
of medicine. The present study aims to provide a brief over-
view of BMIs and how novel clinical data applications can
be developed to derive new knowledge from existing data
to advance clinical care and scientific research of NDD in
the era of precision medicine (PM). The generation and orga-
nization of big data and its application in healthcare settings
depend on a scientific infrastructure that anticipates both
the needs of these types of data, as well as, how they may
be used. The National Institutes of Health and the National
Institute of General Medical Sciences support awards such
as the Center for Biomedical Research Excellence grants to
support big data infrastructure and advance data science.
The Center for Neurodegeneration and Translational Neuro-
science is a Center for Biomedical Research Excellence–sup-
ported neuroscience enterprise with a Data Management and
Statistics Core that serves as a platform for investigating how
to apply big data to PM.
1.1. What is PM?
PM has recently been defined as “an emerging approach
for disease treatment and prevention that takes into account
individual variability in genes, environment, and lifestyle for
each person.” [2]. A primary aim of PM is to link individuals
with the best possible treatment for an individual’s disease in
the hope of improving clinical outcomes, and ultimately, pa-
tient health. Effective implementation of PM into clinical
practice requires integration of translational research from
a diverse array of data sources to ensure that the PM
approach is firmly rooted in empirical evidence. Although
individualized approaches to clinical care have been present
for decades, (e.g., matching blood transfusions or solid or-
gan transplants based on blood type), the wealth of data
available in modern medicine, with all its technological ad-
vances, moves the potential for truly precise interventions
far beyond what has historically been possible. NDDs pre-
sent significant opportunity for development of PM interven-
tions [3], not only because of the wealth of genetic
information now available [4,5] but also because of the
concurrent growth in biomarker discovery [6] and the ability
to characterize the cognitive and behavioral phenotype in
rich detail. Moreover, the historical approaches (e.g., one-
size-fits-all treatment) have almost universally failed to un-
cover an effective therapeutic agent [7], which may in part
be due to the incredible diversity in disease manifestations
that can result from the same underlying pathology.
1.2. Biomarkers of neurodegeneration for PM
Definitive diagnosis of NDD requires positive identifica-
tion of the pathologic changes occurring in the brain, which
for most NDD begin decades before the onset of observable
symptoms. As a result, there is considerable interest in the
discovery and validation of reliable biomarkers that could
be used to improve diagnostic accuracy, especially early in
the disease process before the full clinical syndrome is man-
ifest [8]. At present, body fluid analysis and brain imaging
are the two principal sources for biomarker data.
1.3. Fluid biomarkers
Cerebrospinal fluid (CSF) has been a prominent target for
discovery of potential biomarkers, given the possibility that
it provides molecular insights into pathologic processes
within the brain. For example, amyloid b-42 and tau were
two of the earliest validated biomarkers in Alzheimer’s dis-
ease (AD) [9], which has been refined to separate tau into to-
tal tau and phosphorylated tau [10,11]. These CSF markers
have demonstrated good sensitivity to AD pathology and
are widely used in both clinical practice and research.
However, limited specificity [12,13] has mitigated their
utility as stand-alone diagnostics, especially at preclinical
stages [14]. Coupled with the invasive nature of CSF studies,
recent efforts have focused on identification of potential bio-
markers in peripheral fluids (e.g., saliva, blood).
Though there is considerable appeal in a validated blood
test for AD pathology, most efforts to date have not been suc-
cessful [15]. Recent developments, however, have shown
significant promise, with high rates of overall classification
accuracy [16]. If replicated and independently validated,
the simplicity of a blood test would have significant clinical
utility. Once integrated with the clinical history, a blood test
with high sensitivity would make an excellent screening tool
that could be used to quickly and efficiently rule out the pres-
ence of pathology or prompt for additional diagnostic
testing.
1.4. Imaging biomarkers
Brain imaging is also a widely used biomarker, including
both structural and functional imaging. For example, mag-
netic resonance imaging can be used to measure both
regional (e.g., medial temporal structures in AD; frontal at-
rophy in frontotemporal dementia) and whole-brain atrophy,
both of which can be used to inform differential diagnosis
[17]. Several molecular imaging techniques have also been
validated for detecting AD pathology (specifically b amy-
loid), including Pittsburgh compound B [18], and fluorine-
18 labeled radiotracers such as florbetapir [19,20],
florbetaben, and flutemetamol [21]. Cerebral glucose meta-
bolism has also been widely used (e.g., fluorodeoxyglucose
positron emission tomography), both for identification of
early AD-related changes [22] and differentiating them
from other NDDs (e.g., frontotemporal dementia) [23,24].
Tau imaging is increasingly used to identify the state of
tau aggregation in the course of AD [25], which may be
particularly beneficial very early in the disease process
[26]. The noninvasive, or minimally invasive, nature of
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imaging studies makes them among the first biomarkers to
be reviewed in the clinical setting. When integrated with
additional diagnostic studies such as neuropsychological
evaluation or fluid biomarkers, imaging studies can be
particularly informative, both for ruling conditions in, and
ruling conditions out.
1.5. Genomic data
Genetic information is commonly used to assist clinicians
and researchers in guiding differential diagnosis and is also
the central component of PM (e.g., pharmacogenomics). Ge-
netic information is especially useful in identifying at-risk
individuals long before symptoms emerge. For clinical trials
and studies focusing on prevention of disease, this is espe-
cially important because it increases the likelihood of
including those at highest risk of disease. Although there
are specific genes associated with causing early onset AD
(e.g., genes encoding amyloid precursor protein and preseni-
lin 1 and 2) and increasing the risk of late onset AD (e.g., the
e4 allele of the apolipoprotein E) [27], the development of
AD most likely has a polygenic determination [28]. Simi-
larly, several genetic markers have also been associated
with idiopathic Parkinson’s disease [29], dementia with
Lewy bodies [30,31], and frontotemporal dementia [32]. A
common theme across diseases is that there is considerable
heterogeneity in the possible genetic determinants, most
are polygenic disorders, and there is growing evidence of ge-
netic overlap between diseases [28,31,33].
1.6. Cognitive and behavioral markers
Detailed characterization of the clinical presentation,
including both the cognitive and behavioral phenotypes are
core components of a comprehensive diagnostic work up,
whether in clinic or in research participation. At present,
active assessments (i.e., an active and intentional approach
to measuring cognitive functioning and quantification of
behavior) such as cognitive screenings performed in clinic
or detailed neuropsychological evaluation are often used
both to inform differential diagnosis and to establish base-
lines of functioning that can be used to monitor disease pro-
gression over time. The major advantage of active
assessments is the level of control retained by clinicians
and researchers over what measures are used, when they
are administered, and under what circumstances. Moreover,
they can be used to construct a very rich snapshot of func-
tioning that cuts across several domains of ability, and there
is an extensive literature base for these measures.
The challenges with active assessments, however, are that
not only are they labor intensive, slow, and inefficient
[34,35], but most are insensitive to change in the earliest
phases of the disease [8], when intervention may be most
effective. They are also grossly lacking in temporal resolu-
tion, limiting the conclusions that can be drawn at the time
of assessment, forcing clinicians and researchers to either es-
timate previous levels of functioning or make inferences
about the pattern of change between assessments (e.g., that
decline follows a uniformly linear pattern). The ecological
validity of most of these tools is also quite poor, requiring
additional inferences about how observed patterns of perfor-
mance translate to real-world functioning.
One solution is to make better use of technology in the
measurement of human behavior via portable and wearable
devices (e.g., phones, smart watches, and sensors), which
would address many of the limitations of active assessments.
Leveraging portable device platforms would foster the
development of remote assessments that could reduce the
demand on patients and research participants to come to
clinic and provide higher frequency data. Portable platforms
would also increase the opportunities to collect data and
maintain closer contact with patients, which could detect
significant changes sooner and allow intervention earlier if
needed. In addition, portable technology would also allow
for the development and validation of passive data collection
(PDC) methods that could be used to automatically “cap-
ture” data from everyday behaviors (e.g., embedded back-
ground applications, sensors, and so on). These data would
generate an incredibly rich characterization of everyday
cognition and real-world behavior, and because they are
tied directly to an individual through a specific device, the
data would be nearly as unique as a genetic sequence.
When integrated with active assessments, these contin-
uous or high-frequency data capture methods that would
dramatically enrich the overall cognitive and behavioral pro-
file, and many of the shortcomings associated with tradi-
tional active assessments would be mitigated. Although
PDC methods would generate a substantial amount of
“noise” along with the behavioral data, much of this could
be automatically filtered out with concurrent development
of purpose-built informatics applications. Moreover, they
could be used much in the same ways as traditional bio-
markers to detect the presence of underlying NDD. With
proper validation and sufficient classification accuracy,
continuous data capture also has incredibly high clinical util-
ity and efficiency because they are by definition, computer
applications for quantifying everyday behaviors. They do
not place significant demands on the local healthcare system
and require minimal clinician input once deployed.
1.7. What is BMIs?
BMIs has been defined by the American Medical Infor-
matics Association as “the interdisciplinary field that studies
and pursues the effective uses of biomedical data, informa-
tion, and knowledge for scientific inquiry, problem solving,
and decision-making, motivated by efforts to improve hu-
man health” [36]. A core emphasis of BMI is on develop-
ment of technology-driven resources for the storage,
access, use, and dissemination of health-care data to derive
new information and generate new knowledge. There is
currently considerable interest and ongoing work in
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comprehension, integration, and usability of diverse data
sources in BMI, which aligns closely with NDD and PM.
Several distinct, but closely related application areas have
been defined by the American Medical Informatics Associ-
ation. Two of which are particularly important in the study of
NDD—translational bioinformatics and clinical research
informatics.
Translational bioinformatics is defined as “the develop-
ment of storage, analytic, and interpretive methods to opti-
mize the transformation of increasingly voluminous
biomedical and genomic data into proactive, predictive, pre-
ventive, and participatory health.” Given the increasing pre-
cision with which biomedical data are now being collected,
the sheer amount of data that is generated and its complexity,
extracting insights that can be used to inform clinical prac-
tice is a challenge requiring substantial computing power.
However, BMI applications can be developed to detect and
translate the deeply embedded patterns within these data
into predictive treatments tailored to the individual, ulti-
mately leading to improvement in patient outcomes.
Related to translational bioinformatics and somewhat of a
counterpart, clinical research informatics is defined as “the
use of informatics in the discovery and management of
new knowledge relating to health and disease.” Although
highly relevant for clinical trials, clinical research infor-
matics also emphasizes the continued utilization of amassed
data and secondary use and re-use of data, such as electronic
health records and those data aggregated over the course of
routine clinical care, for ongoing research purposes (e.g., pa-
tient registries, collaborative knowledge-bases). Even
though these clinical data are even more complex relative
to the highly controlled and well-characterized data amassed
in a research setting, they serve as the foundation of the
learning health-care system [37]. So, while translational
informatics focuses on moving research evidence from
bench-to-bedside to support evidence-based practice, clin-
ical research informatics aims to generate complementary
practice-based evidence.
1.8. Advancing translational neuroscience research with
BMIs
Over the past several decades, it has become increas-
ingly apparent that NDD cannot be reduced to a single
determinant and attention has shifted to integration of
multidisciplinary data (e.g., biomarker data, imaging data,
genetic data, and cognitive and behavioral phenotypes).
The major challenge, however, is that these “multi-omic”
assessments generate a set of incredibly complex “big”
data. When studied at the level of the individual patient,
these data can be manually integrated relatively easily,
but elucidating patterns within even modest sample sizes
quickly exceed what is feasible with manually guided ap-
proaches. Efficiently and effectively separating the signal
from the noise in such data sets requires dedicated
computing power with purpose-built BMIs applications to
analyze the data and derive novel insights, which is espe-
cially critical for PM.
1.9. Mapping functional networks
NDD is not typified by focal lesions, but rather disruption
of complex neuroanatomical networks [38,39], evident even
in early disease stages [40]. Computational network analysis
is a mathematical modeling approach capable of integrating
diverse data sets and mapping distributed networks by iden-
tifying shared elements (i.e., nodes) and establishing the re-
lationships between them (i.e., edges). It has been effectively
utilized to map both structural and functional connections in
the brain (e.g., [41]) and uncover common genetic pathways
in AD [42]. With sufficient longitudinal data, the evolution
of disease over time can also be modeled [43]. The ability
to model and predict disease course is an essential compo-
nent of PM.
Computational network analysis has also been effectively
used to study diseases that may be best characterized as con-
tinua instead of distinct categorical states and for syndromes
with heterogeneous clinical presentations [44,45]; both of
these are characteristic of NDD. The ability of network
analyses to integrate highly diverse and complex data sets
is a tremendous strength. As data of increasing granularity
become widely available, it may soon be possible to
uncover precise causal relationships driving NDD, which
may lead to the discovery of an effective therapeutic agent.
1.10. Clinical decision support tools
Clinical decisions support (CDS) tools are applications
built to deliver filtered information to providers at the point
of care to enhance health and health care [46]. In essence, a
CDS tool is an application that filters and translates empir-
ical evidence into an immediately usable format to guide cli-
nicians in their clinical decision-making. By integrating
patient-specific parameters (e.g., genetics, biomarker pro-
files), CDS applications can be used to drive PM interven-
tions. CDS applications are not a replacement for clinical
judgment, but rather an additional source of information to
be integrated with clinical judgment in an effort to formulate
personalized treatment recommendations; CDS applications
are a means by which evidence-based practice can be real-
ized.
In AD and related NDD, determining specific treatments
is not yet an issue because there is not an effective therapeu-
tic agent to slow or reverse the underlying pathologic pro-
cess; however, there is a considerable need to develop
tools capable of empirically deriving individualized risk pro-
files. Formulating specific diagnoses based on a set of easily
observed/assessed clinical characteristics (e.g., biomarkers,
behavioral phenotypes) and subsequently developing pre-
dictive algorithms of the patient’s disease course will be
particularly important. In clinical trials, where recruitment
is focusing on very early phases of the disease process, it
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is critical to study those likely to manifest the disease of in-
terest. Being able to accurately identify those with the high-
est risk based on individual parameters will increase
recruitment accuracy, and therefore, the odds of discovering
an effective therapeutic agent.
Machine learning (ML) is a data-driven approach to gener-
ating such predictive algorithms using a set of training data that
are then validated in independent data sets [47,48]. In NDD,
ML could be effectively used to develop statistical models to
establish individual risk profiles and make specific diagnoses
based on a set of individual clinical characteristics. In
supervised learning approaches, researchers identify a
specific endpoint or outcome of interest from a set of data
and allow the program to find and evaluate the underlying
patterns in the remaining data that predict those endpoints.
For example, to develop an algorithm for determining in vivo
amyloid status (i.e., the outcome) based on set of easily
observed clinical characteristics (i.e., the predictors), an
initial set of training data would be required that includes
amyloid status (e.g., florbetapir scan) and potential clinical
characteristics of interest (e.g., volumetric neuroimaging,
cognitive data). The patterns of performance among the
predictors that optimize accurate classification of the output
would then be used to generate an algorithm that could be
applied to a novel data set containing the same predictors.
When provided with performance feedback (i.e., was the
classification correct or incorrect?), the algorithms are
iteratively refined to reduce error rates, effectively “learning”
from experience. While similar classification models can be
built using classical statistical methods (e.g., logistic
regression), hypothesis-driven approaches require researchers
to select predictors of interest based on an a priori assumption;
in complex data sets, this can be particularly challenging and
may not generate the most efficient models.
Even in supervised learning, there is still a need to iden-
tify and label a specific output. In highly complex data sets,
however, there are likely valuable insights embedded within
the data that may be missed using a supervised approach. In
unsupervised learning approaches, researchers allow the
program to explore the underlying structure of the entire
data set without any predetermined endpoint labels; unsu-
pervised learning is especially useful for mining extremely
large and complex data sets, dimension reduction, and un-
covering patterns of data not readily apparent to researchers
through classical hypothesis testing [48,49]. Both supervised
and unsupervised learning methods are being used to extract
valuable insights and develop predictive algorithms from
both data and metadata. When appropriately implemented,
classification and predictions derived from hierarchical, or
deep, learning methods have demonstrated impressive
accuracy comparable with or surpassing human-level accu-
racy [50–52] and are approaching Bayes error rates.
Historically focused on imaging data, systematically
capturing cognitive and behavioral data alongside additional
biological data sources (e.g., structural and functional neuro-
imaging, genetic data, CSF) and subjecting these data to ML
as well may lead to identification of precision biomarkers
associated with specific cognitive and behavioral phenotypes.
The resultingmodels could be used to generate an empirically
derived probability of underlying pathology based solely on
the clinical presentation, which has significant utility for
both clinical trial recruitment and clinical management. For
example, of data of this type might be used to predict evolu-
tion of cognitively normal individuals into amyloid-positive
states, and thus eligibility for clinical trial participation and
eventually for preventative treatment. If integrated into an
electronic medical record along with natural language pro-
cessing application to extract information from clinical notes
(e.g., health record phenotyping), classification models could
be deployed autonomously, and probabilities updated in real
time as new notes are generated. Already validated for use
in screening for common conditions (e.g., type 2 diabetes)
[53] and with fully automated approaches rivaling manual
methods in accuracy [54], extending these applications to
NDD to generate CDS tools to guide treatment selection,
especially if compounds or therapeutics are developed that
have proven efficacy for specific subsets of the disease popu-
lation, would facilitate the practice of PM.
1.11. Transition from state of wellness to disease
One of the major challenges facing NDD is the blurred
boundary between a state of health and one of disease, which
inpart is due to the difficulty detecting the subtle changes asso-
ciated with the transition, as well as clear characterization of
the earliest disease states. Using a complex network approach,
however, it may be possible to identify points of vulnerability
(i.e., tipping points) associated with a development of a clin-
ical syndrome following a period of stability (e.g., Hofmann
et al, 2016) [55]. In NDD especially, where individual differ-
ence factors (e.g., cognitive reserve) can influence the relation-
ship between manifest symptoms and disease burden, being
able to identify factors associated with, or even preceding,
these pathologic transitions may increase opportunities for
intervention. Such approaches have already been used with
neuroimaging data [56,57]. High-throughput data streams
and user-generated data sources (e.g., wearables) providing
behavioral data in real-world settings could then be integrated
with clinical data sources (e.g. electronic medical records).
ML-derived algorithms could then be utilized to automatically
monitor individual data streams andflag patterns of behavioral
that suggest an emerging transition from healthy to disease
states well before the clinical syndrome emerges.
1.12. Modern database infrastructure
In general, development of CDS tools, whether it be for
prediction of disease or for identification of a specific thera-
peutic agent, has required prohibitively large sample sizes to
achieve sufficient stability and reliability. This is especially
the case for identifying the very subtle signals in the earliest
phases of disease. In the absence of distributed collaborative
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networks contributing to a shared data repository, it has been
difficult to aggregate samples of this size. Furthermore,
when sufficiently powered studies were completed, the
data were collected over a predetermined period of time, us-
ing prespecified tools, in a restricted sample, to address an a
priori hypothesis, with highly limited access beyond the
original study investigators. On study completion, these
data were then typically siloed and ended up sitting idle.
Moving these data sets, however, to cloud-based reposi-
tories promotes real-time, open-access data sharing and
collaboration, a movement which has been endorsed by fed-
eral funding agencies and journal editors [58–60]. Creating a
repository to house data collected during the course of
routine clinical care alongside data from ongoing
molecular and genetic research and clinical trials that are
collaboratively aggregated by multiple users would foster
Fig. 1. Precision diagnosis and management of neurodegenerative disease relies on integration of population-level data and individual data derived from mul-
tiple sources. Effective utilization will require informatics applications to aggregate and filter data, which can drive development of clinical decision support
tools for deployment in clinical settings. Developing tools to systematically capture clinical outcomes at the point of service delivery will facilitate refinement of
the clinical decision support tools, creating a learning healthcare system and closing the loop in evidence-based care.
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the development of novel measurement tools, establishment
of clinical normative data, and facilitation of knowledge
discovery via multidisciplinary hypothesis-driven, as well
as, data-driven research (e.g., deep learning, data mining,
andML). Providing open access to datawill also help address
issues of transparency in research, reproducibility of results,
and independent replication, especially when paired with
simultaneous sharing of software and code [61–63].
Although the costs associated with cloud-based storage
were at one point prohibitive for all but the most well-
funded studies or larger enterprise organizations, publicly
available services such as Amazon’s Web Services have
brought leading edge technology within reach for most or-
ganizations. Ultimately, the utility of research and clinical
data are inherently tied to the accessibility of the data,
both within studies and across studies and utilization of
modern data management can dramatically increase acces-
sibility. Making these resources open-access and built using
flexible platforms furthers accessibility and promotes
longevity, allowing perpetual use and re-use of the data
and integration of new data, maximizing return on financial
investments.
2. Conclusion
As the era of personalized medicine continues to evolve
and rich individual data sets become increasingly acces-
sible, development of cloud-based repositories that collab-
oratively aggregate data will rapidly advance basic,
translational, and clinical science. Creating dedicated
BMIs applications with advanced analytic capability de-
signed identify subtle patterns within those data will bring
targeted interventions for NDD based on individually deter-
mined risk profiles within reach. Fig. 1 presents a high-level
overview, tying these concepts together to show how data
from population studies can be aggregated and used to
develop clinical decision support tools, which can then be
deployed in clinical settings, using individual patient data
to guide clinical decision-making. The clinical outcomes
resulting from these decisions are then returned to the
data set, which are used to refine and improve treatment
models and decision support tools, completing the learning
health environment. Ultimately, developing comprehensive
and integrated data environments will lead to improved pa-
tient outcomes and facilitate knowledge discovery,
including disease mechanisms, causal factors, and novel
therapeutics.
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RESEARCH IN CONTEXT
1. Systematic review: Modern medicine is in the midst
of a revolution driven by “big data,” rapidly
advancing computing power, and broader integration
of technology into healthcare. Highly detailed and
individualized profiles of both health and disease
states are now possible, including biomarkers,
genomic profiles, cognitive and behavioral pheno-
types, high-frequency assessments, and medical im-
aging.
2. Interpretation: These individual profiles can be used
to understand multi-determinant causal relation-
ships, elucidate modifiable factors, and ultimately
customize treatments based on individual parame-
ters, which is especially important for neurodegen-
erative diseases, where an effective therapeutic agent
has yet to be discovered.
3. Future directions: By collaboratively aggregating
these data in structured repositories, biomedical
informatics can be used to develop clinical applica-
tions and decision support tools to derive new knowl-
edge from the wealth of available data to advance
clinical care and scientific research of neurodegener-
ative disease in the era of precision medicine.
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